Research on the Status of Patent Protection of Prostaglandin Analogues for Glaucoma in China  

作　　者：Zhou Sheng’an Dong Li 

机构地区：[1]School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China

出　　处：《Asian Journal of Social Pharmacy》2022年第2期178-185,共8页亚洲社会药学（英文）

摘　　要：Objective To study and analyze the status of patent protection of prostaglandin analogues for glaucoma in China.Methods Patent literatures published up to April 7,2020 were retrieved by the keywords“PG”and“prostaglandin”on such patent information service platforms as SIPO,SooPat,and IncoPat.And then they were statistically analyzed by qualitative and quantitative means.Results and Conclusion A total of 300 patent literature related to prostaglandin analogues for glaucoma were obtained,and most of them were invention patents,including patents for composition and dosage form,indications and uses,related synthesis,the compound,and composition preparations.Prostaglandin analogues play an important role in the treatment of glaucoma.At present,China has a large number of patents applications,and the patent protection covers a wide range of technical fields,but the number of patents with valid legal status is relatively small.Therefore,China’s pharmaceutical enterprises and R&D institutions have more options in topic selection and project approval and patent protection strategies.

关 键 词：GLAUCOMA PROSTAGLANDIN patent protection 

分 类 号：O62[理学—有机化学]